GenSight Biologics S.A.
OTC: GSGTF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Laurence Rodriguez
- Employees
- 16
- Headquarters
- Paris, France
- IPO year
- 2018
- Market cap
- $14.7M
- Website
- https://www.gensight-biologics.com
Loading GSGTF…
Loading profile data…Frequently asked questions about GSGTF
What does GenSight Biologics S.A. (GSGTF) do?
GenSight Biologics S.A. is a clinical-stage biotechnology firm dedicated to pioneering, advancing, and bringing to market treatments for serious eye and central nervous system disorders, specifically those linked to mitochondrial dysfunction and neurodegeneration. Their therapeutic pipeline is built upon cutting-edge gene therapy approaches, inc...
Where does GSGTF trade?
GenSight Biologics S.A. (GSGTF) trades on the Other OTC.
What sector is GSGTF in?
GenSight Biologics S.A. (GSGTF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of GenSight Biologics S.A.?
Laurence Rodriguez is the chief executive officer of GenSight Biologics S.A. (GSGTF).
Where is GenSight Biologics S.A. headquartered?
GenSight Biologics S.A. is headquartered in France.
Does GSGTF pay a dividend?
GenSight Biologics S.A. (GSGTF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GSGTF go public?
GenSight Biologics S.A. (GSGTF) completed its initial public offering in 2018.